At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria:

Complete Response/Remission (CR):

• Less than or equal to 5% blasts in the bone marrow

• No evidence of circulating blasts or extramedullar disease

• Full recovery of peripheral blood counts:

  • Platelets > 100,000/μL
  • Hemoglobin ≥ 11 g/dL
  • Absolute neutrophil count (ANC) > 1,500/μL

Complete Remission with only Partial Hematological Recovery (CRh*):

• Less than or equal to 5% blasts in the bone marrow

• No evidence of circulating blasts or extramedullar disease

• Partial recovery of peripheral blood counts:

  • Platelets > 50,000/μL
  • Hemoglobin ≥ 7 g/dL
  • ANC > 500/μL.

Full analysis set (FAS), defined as participants who received any infusion of the assigned study medication, who completed at least the first treatment cycle and for whom at least one response assessment was available after the start of treatment.

At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria:

• Less than or equal to 5% blasts in the bone marrow

• No evidence of circulating blasts or extramedullar disease

• Full recovery of peripheral blood counts:

  • Platelets > 100,000/μL
  • Hemoglobin ≥ 11 g/dL
  • Absolute neutrophil count (ANC) > 1,500/μL

Full analysis set

At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh*) was defined by the following criteria:

• Less than or equal to 5% blasts in the bone marrow

• No evidence of circulating blasts or extramedullar disease

• Partial recovery of peripheral blood counts:

  • Platelets > 50,000/μL
  • Hemoglobin ≥ 7 g/dL
  • ANC > 500/μL.

Full analysis set

At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria:

• Bone marrow blasts ≤ 25%

Full analysis set

A minimal residual disease (MRD) response is defined as MRD < 10^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.

Full analysis set (FAS)

The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.

Full analysis set

Time to hematological relapse was measured for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death.

Hematological Relapse was defined as:

• Proportion of blasts in bone marrow > 5%
• Extramedullary relapse.

Time to hematological relapse was analyzed by Kaplan-Meier methods.

Participants who reached complete remission or complete remission with partial hematological recovery during the core study.

Relapse-free survival was measured only for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.

Participants who reached complete remission or complete remission with partial hematological recovery during the core study.

Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.

Full analysis set

Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 and according to the following:

Grade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death).

The investigator used medical judgment to determine if there was a causal relationship (ie, certain, probable, possible, unlikely, not related) between an adverse event and blinatumomab.

A serious adverse event is any untoward medical occurrence or effect, that at any dose:

resulted in death, was life-threatening, required or prolonged hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is a medically important condition.

Safety analysis set, defined as all participants who received any infusion of blinatumomab.

The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2, respectively. Actual doses administered were used in the analysis.

Concentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.

Participants who received blinatumomab and who had available pharmacokinetic data.

Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m^2/hr) and Css is the steady state concentration.

Participants who received blinatumomab and who had available pharmacokinetic data.

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.

Participants who received blinatumomab and who had evaluable pharmacodynamic data.